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212 The Journal of Thoracic and Cardbjective: Cardiovascular disease is a common cause of morbidity and mortality in
rgan transplant recipients, and cardiac surgery has become more common in this
opulation. We performed a retrospective study of kidney transplant recipients who
nderwent cardiac surgery over the past 10 years at our institution with an emphasis
n evaluating postoperative outcomes.
ethods: Seventy-four patients with previous abdominal transplants underwent
ardiac surgery (93% coronary artery bypass grafting, 5.4% bypass grafting plus
alve, and 1.4% valve) between 1995 and 2005. These recipients were compared
ith 895 adult nontransplant patients undergoing cardiac surgery between 2000 and
005. Only kidney and kidney–pancreas recipients were included in the analysis
n  70) because there were only 2 liver and pancreas alone transplants.
esults: As compared with nontransplant patients, kidney transplant patients were
ounger (mean age 52.1  10 years vs 61  13 years; P  .001) and had an
ncreased incidence of diabetes (92.9% vs 39.1%; P  .001), peripheral vascular
isease (37.1% vs 19.1%; P .001), chronic kidney insufficiency (73.0% vs 13.4%;
 0.001), and unstable angina (44.8% vs 25.7%; P  .005) There was no
ifference between the two groups in the complication rate at 30 days after surgery,
xcept that transplant patients were more likely to have postoperative kidney
ysfunction (32.6% vs 6.1%; P  .001) and require hemodialysis (11.7% vs 1.1%;
 .0001). Thirty-day postoperative mortality was similar between groups (1.4%
s 2.9%; P  not significant). By multivariable analysis, preoperative congestive
eart failure, nonelective surgery, prolonged cardiopulmonary bypass times, periph-
ral vascular disease, and lower creatinine clearance were significant risk factors for
ostoperative mortality; however, prior kidney transplant was not an independent
isk factor for 30-day postoperative mortality.
onclusions: Despite their increased incidence of comorbid conditions, the postop-
rative outcomes of cardiac surgery in kidney transplant recipients are similar to
hose in the nontransplant population except for a higher incidence of kidney
ysfunction in transplant patients.
he excellent long-term results of abdominal organ transplants are leading to
wider applicability, especially in higher risk recipients including older can-
didates and those at risk for cardiac disease. As a consequence, more
ransplant recipients are being referred for the evaluation and treatment of cardio-
ascular disease and, in particular, coronary atherosclerosis.
In 1984, we1 first published our experience at the University of Minnesota with
ardiac surgery in 14 kidney transplant recipients. Herein, we present our recent
xperience with cardiac surgery in a larger series of kidney transplant recipients.
he objectives of this study were (1) to identify the characteristics and risk factorsn kidney transplant recipients who underwent cardiac surgery and (2) to evaluate
iovascular Surgery ● May 2007
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CDheir early mortality and morbidity and changes in kidney
unction as compared with nontransplant patients.
atients and Methods
tudy Population
total of 74 abdominal organ transplant recipients (58 kidney, 12
ombined kidney–pancreas, 2 pancreas, 2 liver) underwent cardiac
urgery at the University of Minnesota Medical Center between
anuary 1995 and October 2005. Of these 74 recipients, 73 under-
ent coronary artery bypass graft (CABG) surgery (5 with com-
ined valve surgery), and 1 underwent valve surgery alone. Be-
ause of the small number of liver alone and pancreas alone
ransplants, they will not be included in our analysis. Of the 70
idney transplant recipients, 38.6% had failed allografts and were
n dialysis at the time of their cardiac surgery. We compared the
utcomes of cardiac surgery in the 70 kidney transplant recipients
ith the outcome in 895 nontransplant patients who underwent
ardiac surgery at out institution between January 2000 and Feb-
uary 2005. Of these 895 nontransplant patients, 699 underwent
ABG surgery (102 with concomitant valve surgery) and 196
nderwent valve surgery alone.
All patients were followed up until death or 30 days after
urgery during the mean follow-up time of 29.5 days (range:
–30). We collected patient data from both the hospital medical
ecords and the institutional data reported to the Society of Tho-
acic Surgeons Database. All patients provided informed consent
nd the registry was approved by our institutional review board.
linical Data
or all patients, we analyzed the following characteristics: pres-
nce of heart disease symptoms, presence or absence of chronic or
nstable angina, physician-defined symptoms of decompensated
eart failure, percutaneous coronary intervention, percentage of
eft ventricular ejection fraction (LVEF) at the time of surgery,
resence of comorbidities, including diabetes, dyslipidemia, hy-
ertension, history of stroke, peripheral vascular disease, renal
unction (serum creatinine concentration [SCr] serum creatinine
learance calculated from Cockroft-Gault equation, chronic hemo-
ialysis), elective versus urgent surgery; crossclamp and perfusion
imes, and postoperative complications. These included cardiac
omplications, such as tamponade, myocardial infarction, reopera-
ion for occlusion or other causes, requirement of intra-aortic
alloon pump support, renal dysfunction defined as rise of SCr
bove 2.5 mg/dL and/or a need for hemodialysis, ventilatory
upport, pneumonia, multiorgan failure, gastrointestinal complica-
ions, leg infection, sepsis, coma, and neurologic complications,
Abbreviations and Acronyms
CABG coronary artery bypass graft
LVEF  left ventricular ejection fraction
RR  relative risk
SCr  serum creatine concentrationnd readmission within 30 days after surgery. d
The Journal of Thoracicreoperative Management
Antibiotics. All patients received preoperative antibiotics be-
ore skin incision, including cephalosporins for CABG surgery and
ancomycin for valve operations. Antibiotics were continued for at
east 24 hours postoperatively, barring other clinical indications for
onger duration of therapy.
Immunosuppression. Immunosuppressive protocols for our
ransplant recipients have been described in detail.2 Maintenance
mmunosuppression was not changed before cardiac surgery.
oses were held while patients were under nothing-by-mouth
rders and restarted within 24 hours after surgery. If the recipient
as not tolerating oral medications within 24 hours, intravenous
oses were given. Dosing of calcineurin inhibitors was also held if
here was significant postoperative kidney dysfunction. Immuno-
uppressive drug levels were monitored and adjusted when neces-
ary. Prophylactic stress doses of corticosteroids were given to all
atients receiving long-term steroid therapy.
ardiac Surgery
n all patients, cardiac surgery was performed with standard sur-
ical techniques through a median sternotomy using cardiopulmo-
ary bypass with membrane oxygenation and moderate systemic
ypothermia (temperature range, 28°C to 32°C). In renal transplant
ecipients, a higher mean perfusion pressure was maintained to
ptimize kidney perfusion. Cold antegrade blood cardioplegia was
sed for all patients with retrograde blood cardioplegia in some
atients for myocardial preservation. Anticoagulation was achieved
efore cardiopulmonary bypass with heparin (300–400 U/kg) to
chieve activated clotting times greater than 400 seconds.
erioperative Care
tandard intensive care unit protocols were used in the immediate
ostoperative care of these patients, including inotropic support
ith dopamine or milrinone. All patients had hemodynamic mon-
toring with a Swan–Ganz catheter (Edwards LifeSciences, Irvine,
alif) to closely monitor cardiac function and intravascular vol-
me status.
Patients who were dialysis-dependent underwent their usual
aintenance hemodialysis the day before surgery. During surgery,
arge-volume hemofiltration was carried out by the perfusion team
uring cardiopulmonary bypass. Additionally, these patients were
losely followed up by the kidney service to determine the fre-
uency and timing of postoperative dialysis, in conjunction with
he cardiothoracic surgical team.
ollow-up
ll patients were seen by the surgical team about 2 weeks after
ischarge. They were also routinely followed up by the appropriate
ransplant and cardiology services.
omplications and Causes of Death
dverse events and causes of death were characterized by the
ttending physician. Autopsy results were not available.
tatistical Analysis
ifferences between the two groups were examined by the 2 or
isher exact test. Continuous variables were compared by a Stu-
ent t test if normally distributed; if not, a Wilcoxon rank-sum test
and Cardiovascular Surgery ● Volume 133, Number 5 1213
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A
CDas used. Survival estimates were based on the Kaplan–Meier
ethod and compared with log-rank statistics. To identify preop-
rative risk factors for perioperative 30-day mortality after cardiac
urgery, we entered parameters (Table 1) into our univariate anal-
sis model. The covariates, which correlated with end points on
nivariate analysis at P value  .15, were entered and allowed to
tay in a stepwise multiple logistic regression model at a P value
f  .15. Values are reported as mean  standard deviation. All
ata were analyzed by the SAS system software version 9.0 (SAS
nstitute, Inc, Cary, NC).
esults
atient Characteristics
he demographics of transplant recipients and control sub-
ects undergoing cardiac surgery are shown in Table 1.
ransplant patients were predominantly white men with a
ean age of 52.1 years. The majority of these patients had
ore than one major cardiovascular risk factor, were
ounger, had lower body mass index, were less likely to
moke or have dyslipidemia, but were more likely to have
eripheral vascular disease We found no statistically signif-
cant differences between the two groups in regard to gen-
er, ethnicity, prevalence of hypertension, or history of
trokes (Table 1).
idney Function
he majority (68.6%) of transplant recipients who under-
ent cardiac surgery had abnormal kidney function—SCr
as greater than 2 mg/dL in 30% and 38.6% had returned to
emodialysis (Table 2). As compared with nontransplant
atients, transplant recipients had significantly worse kid-
ey function. Transplant recipients were also four times
ore likely to be receiving hemodialysis before their car-
ABLE 1. Patient characteristics
Nontransplant,
n  895 (%)
Transplant,
n  70 (%) P value
emographics
Female gender 31.8 28.6 .57
White ethnicity 90.9 92.5 .66
Age 50 y 79.0 41.4 .001
Mean age  SD (y) 61.0 13.6 52.1 9.9 .001
Mean body mass
index (kg/m2)
28.7 5.9 27.1 5.3 .01
omorbidities
Diabetes 39.1 92.9 .001
Tobacco use 50.8 38.6 .05
Dyslipidemia 67.4 51.4 .006
Hypertension 76.2 82.8 .20
History of strokes 7.9 8.6 .85
Peripheral vascular
disease
19.1 37.1 .001iac surgery. i
214 The Journal of Thoracic and Cardiovascular Surgery ● Malinical Presentation
t the time of cardiac surgery, 37% of kidney transplant
ecipients had symptoms of decompensated heart failure;
ew York Heart Association functional class III or IV was
resent in the majority (81%) of patients; 23% of recipients
ad a mean LVEF of 40% or less (Table 3). There were no
tatistically significant differences between kidney trans-
lant recipients and nontransplant recipients with regard to
he prevalence of heart failure at time of surgery, New York
eart Association functional class distribution, history of
yocardial infarction, percutaneous coronary vascular in-
ervention, and mean LVEF (Table 3).
Unstable angina before cardiac surgery was less common
ABLE 2. Kidney function
Nontransplant,
n  895,
mean  SD (%)
Transplant,
n  70,
mean  SD (%) P value
ean SCr (mg/dL) 1.47 1.4 3.73 2.4 .001
ean SCr clearance
(mL · kg1 · min1)
82.16 47.7 38.6 27.2 .001
everity of renal
insufficiency
SCr  2 mg/dL, no
hemodialysis
87.3 31.4 .001
SCr  2 mg/dL, no
hemodialysis
5.1 30.0 .001
Hemodialysis 7.6 38.6 .001
Cr, Serum creatinine concentration.
ABLE 3. Clinical presentation
Nontransplant,
n  895,
mean  SD (%)
Transplant,
n  70,
mean  SD (%)
P
value
ardiac angina
No angina 31.8 47.1 .008
Chronic angina 23.3 30 .21
Unstable angina 25.7 22.8 .001
unctional capacity
NYHA class I 4.6 1.7 .31
NYHA class II 16.9 17.2 .94
NYHA class III 57.2 60.3 .63
NYHA class IV 21.4 20.7 .90
ongestive heart failure 28.2 21.4 .22
istory of myocardial
infarction
39.8 37.1 .66
ascular intervention
with/without PTCA
38.8 37.1 .79
VEF
LVEF 40% 31.5 23.4 .18
Mean % LVEF 49.1 15.5 51.2 12.6 .28
YHA, New York Heart Association; PTCA, percutaneous transluminal
oronary angioplasty; LVEF, left ventricular ejection fraction.n kidney transplant recipients than in nontransplant pa-
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A
CDients, and kidney transplant recipients more often presented
ithout anginal symptoms as compared with nontransplant
atients undergoing cardiac surgery.
ardiac Surgery
he majority (98.5%) of the 70 kidney transplant recipients
nderwent CABG surgery (with or without concomitant
alve surgery) and 1.4% underwent valve surgery alone. Of
hese cardiac operations, most were elective. Only 8.6% of
atients had a significant (50%) left main coronary artery
esion. For revascularization, the internal thoracic artery
as used in 62.3% of those who underwent CABG surgery.
s compared with 895 nontransplant patients, kidney trans-
lant recipients were more likely to undergo elective sur-
ery (68.6% vs 55.9%; P  .04), more likely to undergo
ABG surgery rather than valve surgery alone (98.5% vs
8.1%; P  .002), less likely to have significant left main
oronary disease (8.6% vs 18%; P  .04), and less likely to
ave the internal thoracic artery graft for revascularization
62.3% vs 88.3%; P  .001). Transplant recipients also had
horter crossclamp time (95.3  46.3 minutes vs 112.7 
2 minutes; P  .009) and shorter perfusion time (141.3 
4.8 minutes vs 160  68.4 minutes; P  .01).
utcomes of Cardiac Surgery
Nonrenal complications. During the first 30 postopera-
ive days, nearly half (47%) of transplant recipients who
nderwent cardiac surgery had at least one postoperative
onrenal complication. The most common included need
or ventilatory support (11.4%), systemic infection or sepsis
2.9%), postoperative myocardial infarction (2.9%), neuro-
ogic complication or coma (2.9%), pneumonia (1.4%),
ultiorgan failure (1.4%), gastrointestinal complications
1.4%), and limb ischemia (1.4%) (Table 4).
However, there was no significant difference between
ransplant and nontransplant recipients in the incidence of
ABLE 4. Thirty-day nonrenal complications
Nontransplant,
n  895 (%)
Transplant,
n  70 (%) P value
rolonged ventilatory support 18.3 11.4 .14
eg infection 2.0 2.9 .63
epsis 1.7 2.9 .47
yocardial infarction 1.7 2.9 .47
oma for 24 h 1.1 2.9 .21
eurologic 2.3 1.4 .62
ultiorgan failure 1.1 1.4 .81
astrointestinal 4.7 1.4 .20
neumonia 6.7 1.4 .08
amponade 1.0 0 .40
ther 30 20 .15onrenal postoperative complications. There was a trend f
The Journal of Thoracicoward higher incidence of postoperative pneumonia in
ontransplant patients.
Kidney dysfunction. The likelihood of postoperative
idney dysfunction developing within 30 days after surgery
as higher in transplant than nontransplant recipients.
mong patients who were not hemodialysis-dependent at
he time of surgery, postoperative kidney dysfunction de-
ned by a need for hemodialysis or a rise of SCr greater
han 2 mg/dL developed in 32.6% of transplant recipients
14/43) as compared with 6% of nontransplant patients
50/827) (P  .001).
The likelihood that kidney allograft function would
orsen after cardiac surgery correlated with the baseline
reoperative SCr. In transplant patients with SCr greater
han 2 mg/dL, 47.6% (10/21) had a postoperative SCr
levation versus 18.2% (4/22) of those with preoperative
Cr of 2 mg/dL or less (P .04). Similar trends were observed
n nontransplant patients; of those with baseline SCr greater
mg/dL, 21.7% (10/46) had a postoperative SCr rise versus
% (40/781) of patients with baseline SCr of 2 mg/dL or
ess (P  .001).
Long-term kidney function. Of the 14 transplant pa-
ients who had postoperative kidney dysfunction (defined as
need for hemodialysis or a rise of SCr  2 mg/dL), 3
equired temporary hemodialysis and 11 had a rise in SCr
reater than 2 mg/dL. The 3 who required hemodialysis all
egained kidney function and were alive at 5 years of
ollow-up with a functioning allograft. Of the 11 patients
ith a rise in SCr greater than 2 mg/dL, 4 lost allograft
unction 1 year after cardiac surgery and required perma-
ent hemodialysis; of the remaining 7, 1 died within 1 year,
ut 6 were alive at 5 years of follow-up with a functioning
llograft. Thus, the overall 5-year dialysis-free survival of
ransplant recipients in whom kidney dysfunction developed
fter cardiac surgery was 64.2% (9/14).
Reoperation and readmission. Overall, only 8.6% of
ransplant recipients required cardiac reoperation (including
ABLE 5. Thirty-day outcomes
Nontransplant,
n  895 (%)
Transplant,
n  70 (%)
P
value
eoperation 4.7 2.9 .48
Vessel occlusion 0.7 1.4 .47
Other causes 2.1 0 .21
urvival
30-day survival 97.1 98.6 .47
No. of deaths 26/894 1/70
auses of death Cardiac (n  20) CVA (n  1)
CVA or neurologic
(n  4), renal (n  1),
and pulmonary (n  1)
VA, Cerebrovascular accident.or bleeding) and 8.6% of patients required readmission
and Cardiovascular Surgery ● Volume 133, Number 5 1215
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CDithin 30 days after surgery. There were no differences in
he incidence of cardiac reoperation between transplant and
ontransplant patients (Table 5). However, there was a
onsignificant trend toward lower rates of readmission in
ransplant patients (8.6% vs 15.1%; P  .14).
Thirty-day mortality after cardiac surgery. The 30-day
ostoperative mortality rate did not differ between trans-
lant and nontransplant patients. Of the transplant recipients
ho underwent cardiac surgery, 1 died within 30 days
ostoperatively (cerebrovascular accident) (Table 5). Car-
iac complications were the main causes of postoperative
eaths in nontransplant patients (Table 5).
Risk factors for 30-day mortality. Using multivariate
nalysis, we identified the following factors to be significant
redictors for 30-day mortality: perfusion time greater than
80 minutes (relative risk [RR]  7.18; P  .001), symp-
oms of congestive heart failure (RR  3.47; P  .001),
rgent or emergency cardiac surgery versus elective surgery
RR  3.33; P  .002), and LVEF less than 40% at time of
urgery (RR  2.89; P  .04) (Table 6). Additionally, a
rend toward increased risk of 30-day mortality was seen in
atients with a history of peripheral vascular disease (RR 
.95; P .06) and those with SCr clearance less than 60 mL
kg1 · min1 (RR  2.27; P  .07). Importantly, a
revious kidney transplant was not an independent risk
actor for 30-day postoperative mortality.
iscussion
ardiovascular disease is a major risk factor for adverse
vents in kidney and kidney–pancreas transplant recipients.
atients with end-stage renal disease are especially at high
isk for death from cardiac causes.3,4 Between 1997
nd1999, the death rate for US dialysis patients was 239 per
000 patient-years, and cardiac disease accounted for 44%
f all causes of death.5 In a retrospective study of 2694 adult
idney transplant recipients at the University of Minnesota,
he overall incidence of adverse cardiovascular events, in-
luding myocardial infarction, within 30 days after trans-
ABLE 6. Risk factors for 30-day mortality after cardiac su
Univariate analysis
erfusion time (min) 8.78 (3.47–22.2)
ymptoms of CHF 6.62 (2.86–15.3)
onelective surgery 3.90 (1.63–9.32)
eripheral vascular disease 2.78 (1.27–6.08)
VEF 40% 4.70 (2.09–10.6)
Cr Cl 60 mL · kg
1
· min1 2.16 (0.99–4.72)
lamp time (min) 4.00 (1.75–9.18)
ypertension 3.91 (0.92–16.6)
oronary intervention 2.78 (1.26–6.15)
emale gender 1.76 (0.81–3.80)
HF, Congestive heart failure; LVEF, left ventricular ejection fraction; SCrlant was 6.1%.6 c
216 The Journal of Thoracic and Cardiovascular Surgery ● MaIn addition to the short-term risks, cardiovascular events
re the most common cause of death with functioning
idney allografts. In a study of our recipient population,
7% of deaths in kidney transplant recipients with function-
ng grafts were due to myocardial infarction and 15% were
ue to sudden death (presumably due to arrhythmias).7
idney transplant recipients are at markedly increased risk
or cardiovascular disease for numerous reasons.8 For many
ecipients (eg, those with diabetes or hypertension), the
rimary disease itself is associated with increased cardio-
ascular risk. In other recipients hypertension, hyperlipid-
mia, and hyperhomocysteinemia develop in association
ith kidney failure. Excess risk also may be due to the
emodynamic and metabolic factors that occurred during
he pretransplant interval of chronic renal insufficiency (eg,
nemia, proteinuria, increased extracellular volume, electro-
yte imbalance, and higher levels of thrombogenic factors).9
atients in kidney failure are at higher risk for mitral and
ortic valve calcification, as well as for coronary artery
alcification.10 Postransplant hyperlipidemia, diabetes, and
ypertension related to immunosuppressive regimens con-
inue to place these recipients at increased risk.11
Reports show that simultaneous kidney–pancreas trans-
lantation prolongs the survival of patients with end-stage
enal disease as compared with kidney transplantation
lone, possibly by decreasing cardiac causes of death.12
everal studies have shown that the presence of a function-
ng pancreas graft has favorable effects on lipid profiles,
educes the progression of coronary atherosclerosis, im-
roves cardiac function, and reduces death rates from car-
iovascular causes when compared with kidney-alone trans-
lant recipients.13-15 Patients after liver transplant, a group
ithout the traditional risk factors for cardiovascular dis-
ase as seen in kidney transplant recipients, have a greater
han 10% incidence of adverse cardiovascular events after
ransplantation.16 Thus, it is not surprising that recipients of
olid organ abdominal transplants have a high incidence of
y (n  965)
P value Multivariate analysis P value
.001 7.18 (2.68–19.19) .001
.001 3.47 (1.26–9.58) .001
.001 3.33 (1.24–8.90) .002
.008 2.95 (1.22–7.1) .006
.001 2.89 (1.08–7.73) .04
.05 2.27 (0.93–5.59) .07
.001
.05
.008
.15
rum creatinine clearance.rgerardiovascular disease, often necessitating cardiac surgery.
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A
CDA transplant recipient is considered to be a high-risk
andidate for cardiac surgery because of numerous risk
actors, including coexisting immunosuppression (including
ong-term steroid use with its attendant complications), the
nherent possibility of other end-organ dysfunction, and
arying degrees of primary allograft dysfunction. In addition,
ardiac surgery itself could adversely affect graft function
nd possibly lead to graft loss. Our current study found that
0-day mortality and morbidity rates were similar in trans-
lant recipients and nontransplant patients. Smaller single-
enter studies have similarly reported low mortality after
ardiac surgery in kidney transplant recipients.17-22 How-
ver, a large study from the United States Renal Data
ystem database involving 1100 kidney transplant recipi-
nts undergoing CABG reported an in-hospital mortality
ate of 5.0% with and 9.4% without internal thoracic artery
se.23 Despite the higher mortality rates noted in this study,
ong-term survival was better after surgical revasculariza-
ion than after percutaneous coronary intervention.
In our current study, we noted low rates of re-exploration
or bleeding in transplant versus nontransplant patients.
his low rate may be due to the use of dialysis on the day
efore surgery as well as hemofiltration during cardiopul-
onary bypass. The beneficial effect of aprotinin on post-
perative bleeding must be balanced in view of the recently
eported adverse kidney effects in patients having cardiac
urgery.24 Even though we did not use off-pump approaches
or coronary revascularization in this experience, this tech-
ique has theoretical benefits of reduced incidence of bleed-
ng and neurologic complications.25 Some studies have sug-
ested, however, that off-pump surgery could be associated
ith incomplete coronary revascularization and reduced
raft patency, and the need for and the risk-benefits of this
pproach must be decided on an individual basis.26,27 A
ecent large study also reported a morbidity and mortality
enefit with the use of off-pump CABG in patients under-
oing dialysis.28
Of note, increasing evidence supports the short- and
ong-term morbidity and mortality benefits of maintaining
ormoglycemia in patients undergoing CABG.29 In the past
years, in all of our cardiac patients, we have established
trict blood sugar control protocols, which may have helped
eep our morbidity rates low. In contrast to our low mor-
idity rate, our increased incidence of postoperative kidney
ysfunction in the transplant recipients was alarming. In
oth our study and others, preoperative kidney insufficiency
as a significant risk factor for postoperative kidney failure.
n patients with preoperative kidney insufficiency, the inci-
ence of acute allograft failure is as high as 30%.21 Our high
ncidence of kidney complications leaves much room for
mprovement. One study reports a lower incidence of kid-
ey dysfunction in kidney transplant patients who had off-
ump coronary revascularization.21 Improved strategies
The Journal of Thoracicith the use of possible kidney protective agents during
ardiopulmonary bypass are necessary to reduce the mor-
idity associated with postoperative kidney dysfunction.
Most patients who have kidney dysfunction after cardiac
urgery, including those who require temporary hemodial-
sis, will have return of allograft function. Encouragingly,
ur study showed that 64.2% of such patients were alive and
ialysis-free 5 years after cardiac surgery. Aggressive at-
empts to preserve kidney function, avoidance of nephro-
oxic medications, and the continued involvement of the
idney transplant team are imperative to allow for maximal
eturn of function.
Our study has all the limitations inherent to a retrospec-
ive study. In addition, although results on early morbidity
nd short-term survival are important, longer-term follow-up
ould be valuable, including data on graft patency and
reedom from valve degeneration. A significant proportion
f our transplant recipients were already receiving hemodi-
lysis, raising the question of whether or not these patients
hould be included in the transplant cohort. We included
hem because, even though they had graft failure and were
eceiving hemodialysis, it is our practice to keep them on
aintenance immunosuppression.
In conclusion, our study provides useful data on the
atient characteristics and on postoperative morbidity and
ortality. It represents the largest single-center report of
ardiac surgery in kidney and kidney–pancreas transplant
ecipients. Although the transplant recipients had an in-
reased incidence of preoperative high risk factors, their
ostoperative mortality was low. Importantly, our multiva-
iable analysis showed that a previous kidney transplant was
ot a risk factor for increased mortality after cardiac
urgery.
We thank Mary E. Knatterud, PhD, for editorial assistance.
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iscussion
r Patricia Thistlethwaite (San Diego, Calif). The strength and
readth of solid organ transplantation at the University of Minne-
ota have allowed for the creation of one of the largest groups of
ransplant patients for the study of cardiovascular disease.
With data from the United Network for Organ Sharing sug-
esting that kidney transplant patients survive on the average
etween 10 and 23 years depending on whether the organ was
rom a deceased or living donor and 25 years plus for an HLA
dentically matched donor, and with long-term survivals for kid-
ey–pancreas transplants approaching 10 to 20 years, it is not
urprising that cardiac disease is developing in these individuals
ver time. It is reassuring to see actual data about the safety of
ardiac surgery in patients with transplant allografts.
I have the following questions. What is the effect of immuno-
uppression on wound healing in cardiac surgery? Were the people
ho had wound complications in your group receiving higher
oses of prednisone or FK506? Did infection develop in any
atients who were on a steroid-free protocol? Should patients be
apered down or off steroids before their cardiac operation?
Dr John. Clearly the presence of immunosuppression did not
ffect the incidence of mediastinal and leg wound infection or
ultiorgan sepsis; however, an important immunosuppressant that
learly affects wound healing is rapamycin. We do not have much
xperience with this agent because none of these patients was
eceiving it. However, that clearly is one immunosuppressive
gent that has been shown to markedly increase the risk of wound
ehiscence and multiple problems related to wound healing. All
hese patients were on immunosuppression. I do not have the data
s to whether any of these patients were off steroids, but clearly
ith the low incidence of wound infection in both groups I would
peculate that the presence of immunosuppression has not ad-
ersely affected wound healing.
Dr Thistlethwaite. During cardiac surgery should all solid
rgan transplant patients be treated the same? For example, do you
odify perfusion pressure for individuals with worse organ func-
ion, and would you suggest the routine use of aprotinin during
ases?
Dr John. My personal bias over the past 3 or 4 years has been
o use aprotinin with even mild to moderate degrees of renal
ailure, maybe again based on some of the data to reduce the dose
f aprotinin if the creatinine concentration was increased. In view
f the recent report that all of us are aware of, I have refrained from
sing aprotinin.24 That report, at least, shows that there has been
ncreased incidence of renal failure with aprotinin. Again, some-
hing that we do routinely is to tell the perfusionist to maintain a
igher perfusion pressure during cardiopulmonary bypass. It
ould have been nice to have definitive data to show what that
ressure should be and in the event that those pressures were not
aintained if those patients suffer adversely from increased risk ofenal complications postoperatively.
y 2007
Dr Thistlethwaite. Was intra-aortic balloon pumping used in
any cardiac operations on kidney transplant patients? If so, from
which groin side was it placed? Was the fate of the allograft
different in any of these cases?
Dr John. Good question. It is something that we did not look
at but probably should.
Dr Thistlethwaite. Finally, when a valve replacement needs to
be performed in a patient with a kidney or liver transplant that will
require allograft biopsy in the future, what kind of valve do you
select and how do you manage their warfarin sodium (Coumadin)?
Dr John. I would treat that as I would with a nontransplant
recipient, again presenting the risks and benefits of a tissue versus
a mechanical valve. With increasing data that the tissue valves
have a longer freedom from degeneration as compared with 10
years ago, I now favor the use of tissue valves in renal transplant
patients to obviate the bleeding complications of biopsies and the
other adverse effects of warfarin. I would clearly recommend the
use of a tissue valve in these patients.
Dr David Follette (Sacramento, Calif). I too enjoyed your
presentation. I am still bothered by the fact that you included
patients with failed renal allografts in your analysis. The real
question is, in patients with functioning transplants, does cardiac
surgery have an adverse effect on those transplants? Those patients
were all receiving dialysis. Even if they were on a low dose of
immunosuppression, at least the way my anticipation in reading
your abstract was, I wanted to know what happened with patients
who had transplants and you reduce your n size down to 40 from
70. Perhaps you could tell us in a little bit more detail why you
included patients who had failed transplants in your analysis.
Dr John. It was something that we grappled about and we finally
decided to include them. As you know, most if not all of these patients
are on immunosuppression. I was initially surprised that patients with
failed allografts are on immunosuppression, and the reason that I
obtained on discussion with one of the renal transplant physicians was
twofold. One is that the presence of immunosuppression in a patient
with a failed renal allograft will prevent the development of anti-HLA
antibodies. Their development would be a contraindication for a
second renal transplant, which is always considered in a patient with
a failed allograft. The second reason for having maintenance immu-
nosuppression even though they have chronic failed grafts is to
prevent the occurrence of acute rejection, which can still happen in a
failed organ. An acute rejection could make these patients especially
sick. For both of these reasons they are on maintenance immunosup-
pression. That is why we included patients with failed allografts with
the renal transplant. The good news is that even if we took that away,
the message is still the same. The operative mortality is low and
morbidity is comparable except for a higher incidence of renal dys-
function. Those were the reasons that we clumped them together.
Dr Michael Davidson (Boston, Mass). Given your excellent
results and also your large patient population, I would be interested
to know whether there are any plans to do any kind of comparison
between surgical revascularization as you have done and percuta-
neous revascularization. That might be an interesting question in
terms of how these patients fare with percutaneous coronary in-
terventions, not only in terms of their transplant but also in terms
of what their revascularization success is over time comparing
surgical versus percutaneous in this particular patient population.
Dr John. I will answer that very briefly. It is hard to make a
comparison from this study. About 40% of our patients who under-
went CABG with a renal transplant had previous coronary interven-
tions. From the larger United States Renal System database, even
though the initial operative mortality was higher in renal transplant
patients than in those with percutaneous coronary intervention, long-
term survival was significantly better with surgical revascularization.
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